BJC:CpG岛甲基化表型与CRC预后无关

2016-11-12 MedSci MedSci原创

之前的研究已经表明,CpG岛甲基化表型(CIMP)对结直肠癌(CRC)的预后有不利影响。。然而,样本往往是有限的,只有少数的研究能够调整相关分子特征与分布。本研究的目的是,探讨大型人群研究中CIMP对CRC生存的影响。 研究纳入2003-2010年诊断的1385例CRC患者,分析CIMP状态和其他分子肿瘤的特点。中位数随访时间4.9年。 CIMP-H更常见于年龄更大、女性、近端结肠癌、

之前的研究已经表明,CpG岛甲基化表型(CIMP)对结直肠癌(CRC)的预后有不利影响。然而,样本往往是有限的,只有少数的研究能够调整相关分子特征与分布。本研究的目的是,探讨大型人群研究中CIMP对CRC生存的影响。

研究纳入2003-2010年诊断的1385例CRC患者,分析CIMP状态和其他分子肿瘤的特点。中位数随访时间4.9年。

CIMP-H更常见于年龄更大、女性、近端结肠癌、BRAF基因突变和MSI-H患者中。

然而,CIMP状态与CRC患者(总生存率:HR=1.00; 95% CI=0.72–1.40;疾病特异性生存率:HR=0.96; 95% CI=0.65–1.41)或其他亚组患者的预后无关。

虽然CIMP状态与MSI-H和BRAF突变存在相关性,不过MSI-H (HR=0.49; 95% CI=0.27–0.90)和BRAF突变(HR=1.78; 95% CI=1.10–2.84)对预后的影响是独立于CIMP状态的。

不管是CIMP-低/阴性组,还是CIMP-高组,化疗对CRC患者的预后有类似的好处。

调整其他重要的临床因素和相关基因突变后,CpG岛甲基化表型与CRC预后无关。

原始出处:

Min Jia1, Lina Jansen1, Viola Walter1, Katrin Tagscherer2,3, Wilfried Roth.No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.British Journal of Cancer advance online publication 3 November 2016

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1827236, encodeId=a12b182e23623, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 15 20:54:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783798, encodeId=90de1e8379837, content=<a href='/topic/show?id=6413516394' target=_blank style='color:#2F92EE;'>#CpG岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5163, encryptionId=6413516394, topicName=CpG岛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Jul 16 23:54:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535117, encodeId=c9bd153511e0c, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon Nov 14 12:54:00 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2017-01-15 yxch36
  2. [GetPortalCommentsPageByObjectIdResponse(id=1827236, encodeId=a12b182e23623, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 15 20:54:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783798, encodeId=90de1e8379837, content=<a href='/topic/show?id=6413516394' target=_blank style='color:#2F92EE;'>#CpG岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5163, encryptionId=6413516394, topicName=CpG岛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Jul 16 23:54:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535117, encodeId=c9bd153511e0c, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon Nov 14 12:54:00 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2017-07-16 dingxiaobo
  3. [GetPortalCommentsPageByObjectIdResponse(id=1827236, encodeId=a12b182e23623, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Jan 15 20:54:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783798, encodeId=90de1e8379837, content=<a href='/topic/show?id=6413516394' target=_blank style='color:#2F92EE;'>#CpG岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5163, encryptionId=6413516394, topicName=CpG岛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Jul 16 23:54:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535117, encodeId=c9bd153511e0c, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Mon Nov 14 12:54:00 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2016-11-14 tastas

相关资讯

Cell & NEJM:全球癌症基因组图谱计划又一研究突破 阐明致死性肾癌的发病机制

最近,发表在国际杂志the New England Journal of Medicine上的一篇研究论文中,来自从事癌症基因组图谱(The Cancer Genome Atlas)研究计划的科学家通过进行研究,对第二种常见类型的肾癌的两种类型进行了分子特性的分析,并且对这种常见类型的肾癌进行了不同的分类。 每年乳头状肾细胞癌 (Papillary renal cell carcinoma)